The Trump administration’s announcement on new US tariffs targeting pharmaceutical imports is likely still weeks away, according to officials and industry sources, despite earlier expectations for a mid-year decision, Reuters reported.

The Commerce Department is investigating whether reliance on foreign-made drugs and ingredients poses a national security risk under Section 232 of the Trade Expansion Act. The review, covering finished medicines and active pharmaceutical ingredients, could lead to phased-in tariffs starting small and potentially rising to 250 percent.

Officials say the delay comes as the White House prioritizes other matters, including a US-Russia summit and a separate semiconductor probe expected to conclude first. The pharmaceutical sector has so far been exempt from broader Trump-era tariffs, though future duties could affect global suppliers despite trade deals with key allies, according to Reuters.